ZA200101566B - Sequences characteristic of hypoxia-regulated gene transcription. - Google Patents
Sequences characteristic of hypoxia-regulated gene transcription. Download PDFInfo
- Publication number
- ZA200101566B ZA200101566B ZA200101566A ZA200101566A ZA200101566B ZA 200101566 B ZA200101566 B ZA 200101566B ZA 200101566 A ZA200101566 A ZA 200101566A ZA 200101566 A ZA200101566 A ZA 200101566A ZA 200101566 B ZA200101566 B ZA 200101566B
- Authority
- ZA
- South Africa
- Prior art keywords
- hypoxia
- polynucleotide
- seq
- gene
- functional analogs
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 207
- 206010021143 Hypoxia Diseases 0.000 title claims description 101
- 230000007954 hypoxia Effects 0.000 title claims description 79
- 230000001105 regulatory effect Effects 0.000 title claims description 54
- 238000013518 transcription Methods 0.000 title description 10
- 230000035897 transcription Effects 0.000 title description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 66
- 150000007523 nucleic acids Chemical group 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 102000040430 polynucleotide Human genes 0.000 claims description 29
- 108091033319 polynucleotide Proteins 0.000 claims description 29
- 239000002157 polynucleotide Substances 0.000 claims description 29
- 230000007170 pathology Effects 0.000 claims description 22
- 108091034117 Oligonucleotide Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000028867 ischemia Diseases 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 238000001415 gene therapy Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000001146 hypoxic effect Effects 0.000 claims description 12
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 11
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 11
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 98
- 230000014509 gene expression Effects 0.000 description 59
- 241000282414 Homo sapiens Species 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 35
- 230000000692 anti-sense effect Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 25
- 238000000636 Northern blotting Methods 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000013603 viral vector Substances 0.000 description 15
- 108090000994 Catalytic RNA Proteins 0.000 description 14
- 102000053642 Catalytic RNA Human genes 0.000 description 14
- 101000836394 Homo sapiens Sestrin-1 Proteins 0.000 description 14
- 108091092562 ribozyme Proteins 0.000 description 14
- 230000033115 angiogenesis Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 101000595907 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 description 12
- 102100027288 Sestrin-1 Human genes 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 206010018338 Glioma Diseases 0.000 description 10
- 102100035198 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Human genes 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- -1 8-substituted adenines Chemical class 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 108091060211 Expressed sequence tag Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000007622 bioinformatic analysis Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 101000667821 Homo sapiens Rho-related GTP-binding protein RhoE Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 102100039640 Rho-related GTP-binding protein RhoE Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002503 granulosa cell Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000010249 in-situ analysis Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000007959 normoxia Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000508 neurotrophic effect Effects 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 101150055707 98 gene Proteins 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 229940122439 Hydroxylase inhibitor Drugs 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101100352405 Rattus norvegicus Plod2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 108090001052 hairpin ribozyme Proteins 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000048650 human PLOD2 Human genes 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WYDKPTZGVLTYPG-UHFFFAOYSA-N 2,8-diamino-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(N)N2 WYDKPTZGVLTYPG-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2h-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 description 1
- XZWMZFQOHTWGQE-UHFFFAOYSA-N 6-azathymine Chemical compound CC1=NNC(=O)NC1=O XZWMZFQOHTWGQE-UHFFFAOYSA-N 0.000 description 1
- PFUVOLUPRFCPMN-UHFFFAOYSA-N 7h-purine-6,8-diamine Chemical compound C1=NC(N)=C2NC(N)=NC2=N1 PFUVOLUPRFCPMN-UHFFFAOYSA-N 0.000 description 1
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 1
- 101150091349 95 gene Proteins 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 101100434309 Homo sapiens ADA gene Proteins 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 1
- 101100462513 Homo sapiens TP53 gene Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 101710087370 N-myc protein Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 101710114875 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 description 1
- 102100037681 Protein FEV Human genes 0.000 description 1
- 101710198166 Protein FEV Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101000595912 Rattus norvegicus Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000723677 Tobacco ringspot virus Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000013173 literature analysis Methods 0.000 description 1
- 210000002596 lutein cell Anatomy 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000019039 oxygen homeostasis Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 230000000136 postovulatory effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SEQUENCES CHARACTERISTIC OF
HYPOXIA -REGULATED GENE TRANSCRIPTION
The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of polynucleotide sequences that are differentially expressed in hypoxia and the use of the sequences for diagnosis and probes.
The level of tissue oxygenation plays an important role in normal development as well as in pathologic processes such as ischemia. Tissue oxygenation plays a significant regulatory/inducer role in both apoptosis and in angiogenesis (Bouck et al, 1996; Bunn et al, 1996; Dor et al, 1997; Carmeliet et al, 1998).
Apoptosis (see Duke et al, 1996 for review) and growth arrest occur when cell growth and viability are reduced due to oxygen deprivation (hypoxia). Angiogenesis (i.e. blood vessel growth, vascularization) is stimulated when hypo-oxygenated cells secrete factors which stimulate proliferation and migration of endothelial cells in an attempt to restore oxygen homeostasis (for review see
Hanahan et al, 1996).
Hypoxia plays a critical role in the selection of mutations that contribute to more severe tumorogenic phenotypes (Graeber et al., 1996). Identifying activated or inactivated genes and gene products in hypoxia and ischemia is needed.
Sq wo BN PCT/US99/20394
Ischemic disease pathologies involve a decrease in the blood supply to a bodily organ, tissue or body part generally caused by constriction or obstruction of the ; blood vessels, as for example retinopathy, myocardial infarction and stroke. Therefore, apoptosis and/or . angiogenesis as induced by the ischemic condition are also involved in these disease states. Neocangiogenesis is seen in some forms of retinopathy and in tumor growth. These processes are complex cascades of events controlled by many different genes reacting to the various stresses such as hypoxia.
The ability to monitor hypoxia-triggered activation of genes can provide a tool to identify not immediately evident ischemia in a patient. Identification of hypoxia-regulated genes permits the utilization of gene therapy or direct use of gene products, or alternatively inactivation of target genes for therapeutic intervention in treating the diseases and pathologies associated with hypoxia, ischemia and tumor growth.
The present invention provides purified, isolated and cloned polynucleotides (nucleic acid sequences) associated with hypoxia-regulated activity and having sequences designated as any one of SEQ ID NOS. 142, or having complementary or allelic variation sequences thereto. : :
The present invention provides a method of regulating angiogenesis or apoptosis in a patient in need of such treatment by administering to such patient a therapeutically effective amount of an antagonist of at least one protein as encoded by the nucleic acid sequences , as set forth in any of SEQ ID NOS. 1-12.
wo '‘@> PCT/US99/20394
Also provided is the diagnostic tool for identifying genes modulated by hypoxic conditions having a detector for detecting the presence of a polynucleotide having a nucleic acid sequence according to any of SEQ. ID
NOS. 1-12. A pharmaceutical composition for modulating hypoxia and ischemia having an effective amount of a polynucleotide having the nucleic acid sequence according to SEQ. ID NOS. 1-12 and a pharmaceutically acceptable carrier is also provided.
Also provided is a method of regulating hypoxia- associated pathologies by administering an effective amount of at least one antisense oligonucleotide against one of the nucleic acid sequences (SEQ. ID NOS. 1-12 or their proteins. There is provided a method of regulating hypoxia associated pathology by administering an effective amount of a protein encoded by the polynucleotides (SEQ.
ID NOS. 1-12 as active ingredients in the pharmaceutically . acceptable carrier. Co : Lo
Further, there are provided hypoxia response regulating genes.
Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein: :
Figure 1 shows the nucleic acid sequence of the 92 gene (Seq. I.D. No. 1);
Figure 2 shows the nucleic acid sequence of the 95 gene (Seq. I.D. No. 2);
Figure 3 shows the nucleic acid sequence of the 98 gene (Seq. I.D. No. 3);
Figure 4 shows the nucleic acid sequence of the 60F6 gene (Seq. I.D. No. 4);
Figures 5 A-C show the nucleic acid sequence of the 648 gene: the published human, the cloned human (H648ks) and the cloned rat sequences, respectively (Seq. I.D. Nos:5, 6 and 7, respectively).
Figure 6 shows the nucleic acid sequence of the 24D4 gene (Seq. I.D. No. 8) ;
Figures 7A and 7B show the nucleic acid sequence of the 77H4 gene, clones 77H4 18E and 77H4 3D, respectively (Seq.
I.D. Nos: 9 and 10, respectively).
Figure 8 shows the nucleic acid sequence of the 14G2 gene (Seg. I.D. No. 11); and
Figure 9 shows the nucleic acid sequence of the 29F3 gene (Seq. I.D. No. 12).
The present invention identifies polynucleotides (nucleic acid sequences) with sequences as set forth herein in SEQ. ID Nos. 1-12, that can be utilized diagnostically in hypoxia and ischemia and that can be used as targets for therapeutic intervention, or can be used to identify genes that are regulated and respond to hypoxic conditions. SEQ
ID Nos. 1-4 and 6-12 have not previously been identified.
SEQ ID No. 5 was found to match sequences in data banks but has not been reported to be associated with hypoxia regulation.
wo “@ . PCT/US99/20394
The present invention further provides candidate genes and gene products that can be utilized therapeutically and diagnostically in hypoxia and ischemia and that can regulate apoptosis or angiogenesis.
By regulate or modulate or control, it is meant that the process is either induced or inhibited to the degree necessary to effect a change in the process and the associated disease state in the patient. Whether induction or inhibition is being contemplated will be apparent from the process and disease being treated and will be known to those skilled in the medical arts.
The present invention identifies genes for gene therapy, diagnostics and therapeutics that have direct causal relationships between a disease and its related pathologies and up- or down-regulator (responder) genes.
That is, the present invention is initiated by a physiological relationship between cause and effect. oC The present invention also provides a method of regulating angiogenesis or apoptosis in a patient in need of such treatment by administering to such patient a therapeutically effective amount of an antagonist of at least one protein as encoded by the nucleic acid sequences as set forth in any of SEQ ID NOS. 1-12.
As shown below, some sequences are partial gene sequences which are markers/probes for genes that are upregulated under hypoxic conditions. These partial sequences can be designated "Expressed Sequence Tags" (ESTs) and are markers for the genes actually expressed in vivo and are ascertained as described herein in the
Examples or as is known in the art.
Generally, ESTs comprise DNA sequences corresponding to a portion of nuclear encoded mRNA. The
EST has a length that allows for PCR (polymerase chain reaction), for use as a hybridization probe and is a unique designation for the gene with which it hybridizes (generally under conditions sufficiently stringent to require at least 95% base pairing). For a detailed description and review of ESTs and their functional utility see, WO 93/00353 PCT Application which is incorporated herein in its entirety by reference, as well as the references by Zweiger et al, 1997; Okubo et al, 1997 and Braren et al, 1997.
The WO 93/00353 PCT application further describes how the EST sequences can be used to identify the transcribed genes.
The present invention also provides a method of diagnosing the presence of ischemia or other hypoxia- associated pathologies in a patient including the steps of analyzing a tissue sample from the patient for the presence of at least one expressed gene (up-regulated) identified by the sequences of the present invention utilized as probes. Methods cf identification of hybridization can include immunohistochemical staining of the tissue samples. Further, for identification of the gene, in situ hybridization, Southern blotting, single strand conformational polymorphism, restriction endonuclease fingerprinting (REF), PCR amplification and
DNA-chip analysis using the nucleic acid sequences of the present invention as probes/primers can be used.
Further, according to the present invention, purified, isolated and cloned hypoxia-responding genes identified by the probes/sequences hybridizing under stringent conditions with 95% homology set forth herein or a complementary or allelic variation sequence and human homologies as needed thereto are disclosed. The present invention further provides proteins as encoded by the identified genes. The present invention further provides antibodies directed against these proteins. The present invention further provides transgenic animals and cell lines carrying at least one expressible gene identified by the present invention. The present invention further provides knock-out eucaryotic organisms in which at least one nucleic acid sequences as identified by the probes of the present invention.
The present invention provides a method of regulating angiogenesis, apoptosis or other hypoxia- associated pathologies in a patient in need of such treatment by administering to a patient a therapeutically effective amount of an antagonist of at least one protein as encoded by the nucleic acid sequences or sequences identified herein or by the probes of the present invention, or alternatively by a non-protein product of the gene's activity, or inactivation of a gene by chemical compound. Alternatively, the present invention provides a method of regulating angiogenesis, apoptosis or other hypoxia-associated pathologies in a patient in need of such treatment by administering to a patient a therapeutically effective amount of at least one antisense oligonucleotide against the nucleic acid sequences or dominant negative peptide directed against the sequences or their proteins.
The present invention further provides a method of regulating angiogenesis or apoptosis in a patient in need of such treatment by administering to a patient a therapeutically effective amount of a protein encoded by the identified genes as active ingredients in a pharmaceutically acceptable carrier.
The present invention provides a method of providing an apoptosis-regulating gene, an angiogenesis- regulating gene or hypoxia-response regulating gene identified by the probes of the present invention, by administering directly to a patient in need of such therapy an expressible vector comprising expression control sequences operably linked to one of the identified genes and its human homolog if appropriate.
The proteins of the present invention can be produced recombinantly (see generally Marshak et al, 1996 "Strategies for Protein Purification and Characterization.
A laboratory course manual." CSHL Press) and analogues can be due to post-translational processing. The term
Analogue as used herein is defined as a nucleic acid sequence or protein which has some differences in their amino acid/nucleotide sequences as compared to the native sequence of SEQ. ID NOS. 1-12. Ordinarily, the analogue will be generally at least 70% homologous over any portion that is functionally relevant. In more preferred embodiments the homology will be at least 80% and can approach 95% homology to the protein/nucleotide sequence.
The amino acid or nucleotide sequence of an analogue can differ from that of the primary sequence when at least one residue is deleted, inserted or substituted, but the protein or nucleic acid molecule remains functional. Differences in glycosylation can provide protein analogues.
Functionally relevant refers to the biological property of the molecule and in this context means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a naturally occurring protein or nucleic acid molecule. Effector functions include but are not limited to include receptor binding, any enzymatic activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to extracellular matrix or cell surface molecules, or any structural role as well as having the nucleic acid sequence encode functional protein and be expressible. The antigenic functions essentially mean the possession of an . - 8 - - - ee epitope or antigenic site that is capable of cross- reacting with antibodies raised against a naturally occurring protein. Biologically active analogues share an effector function of the native which can, but need not, in addition possess an antigenic function.
The antibodies can be either monoclonal, polyclonal or recombinant and be used in immunoassays.
Conveniently, the antibodies can be prepared against the immunogen or portion thereof for example a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof can be isolated and used as the immunogen. Immunogens can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY, 1988 and
Borrebaeck, Antibody Engineering - A Practical Guide, W.H.
Freeman and Co., 1992. Antibody fragments can also be prepared from the antibodies and include Fab, F(ab'),, and
Fv by methods known to those skilled in the art.
For producing polyclonal antibodies a host, such as a rabbit or goat, is immunized with the immunogen or immunogen fragment, generally with an adjuvant and, if ~ 25 necessary, coupled to a carrier; antibodies to the immunogen are collected from the sera. Further, the polyclonal antibody can be absorbed such that it is monospecific. That is, the sera can be absorbed against related immunogens so that no cross-reactive antibodies remain in the sera rendering it monospecific.
For producing monoclonal antibodies the technique involves hyperimmunization of an appropriate donor with the immunogen, generally a mouse, and isolation of splenic antibody producing cells. These cells are fused to a cell having immortality, such as a myloma cell, to provide a fused cell hybrid which has immortality and secretes the required antibody. The cells are then cultured, in bulk, and the monoclonal antibodies harvested oo 5 from the culture media for use. 0 CT
For producing recombinant antibody (see generally Huston et al, 1991; Johnson and Bird, 1991; : Mernaugh and Mernaugh, 1995), messenger RNAs from antibody producing B-lymphocytes of animals, or hybridoma are reverse-transcribed to obtain complimentary DNAs (cDNAs).
Antibody cDNA, which can be full or partial length, is amplified and cloned into a phage or a plasmid. The cDNA can be a partial length of heavy and light chain cDNA, separated or connected by a linker. The antibody, or antibody fragment, is expressed using a suitable expression system to obtain recombinant antibody. Antibody
CDNA can also be obtained by screening pertinent expression libraries.
The antibody can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated, as is well known in the art. (For a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone & Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, Oxford, - 25 1982.) The binding of antibodies to a solid support substrate is also well known in the art. (See for a general discussion Harlow & Lane Antibodies: A Laboratory
Manual, Cold Spring Harbor Laboratory Publications, New
York, 1988 and Borrebaeck, Antibody Engineering - A
Practical Guide, W.H. Freeman and Co., 1992). The detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, B-
galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, **C and iodination.
These transgenics and knock-cuts of the present invention are constructed using standard methods knowr. in the art and as set forth in United States Patants 5,487,892, 5,464,764, 5,387,742, 5,360,735, 5,347,075, 5,298,422, 5,288, 846, 5,221,778, 5,175,385, 5,175,384, 5,175,383, 4,736,866 as well as Burke and Olson (1991),
Capecchi (1989), Davies et al. (1992), Dickinson et al. (1993), Duff and Lincoln (1995), Huxley et al. (1991),
Jakobovits et al. (1993), Lamb et al. (1993), Pearson and
Choi (1993), Rothstein (1991), Schedl et al. (1993),
Strauss et al. (1993). Further, patent applications WO 94/23049, WO 93/14200, WO 94/06908, WO 94/28123 also provide information.
More specifically, any techniques known in thes art can be used to introduce the transgene expressibly into animals to produce the parental lines of animals.
Such techniques include, but are not limited to, pronuclear microinjection (U.s. patent 4,873,191); retrovirus mediated gene transfer into germ lines (Van der
Putten et al., 1985); gene targeting in embryonic stem cells (Thompson et al., 1989; Mansour, 1990 and U.S. patent 5,614,396); electroporation of embryos (Lo, 1983); and sperm-mediated gene transfer (Lavitrano et al., 1989).
For a review of such techniques see Gordon (1989).
Further, one parent strain instead of carrying a direct human transgene can have the homologous endogenous gene modified by gene targeting such that it approximates the transgene. That is, the endogenous gene has been "humanized" and/or mutated (Reaume et al, 1996). It should be noted that if the animal and human sequence are essentially homologous a "humanized" gene is not required.
The transgenic parent can also carry an over expressed sequence, either the non-mutant or a mutant sequence and humanized or not as required. The term transgene is therefore used to refer to all these possibilities.
Additionally, cells can be isolated from the
BN offspring which carry a transgene from each transgenic parent and that are used to establish primary cell cultures or cell lines as is known in the art.
Where appropriate, a parent strain will be homozygous for the transgene. Additionally, where appropriate, the endogenous non-transgene in the genome that is homologous to the transgene will be non- expressive. By non-expressive is meant that the endogenous gene will not be expressed and that this non- expression is heritable in the offspring. For example, the endogenous homologous gene could be "knocked-out" by methods known in the art. Alternatively, the parental strain that receives one of the transgenes could carry a mutation at the endogenous homologous gene rendering it non-expressed.
The antagonist/regulating agent /active ingredient is dosed and delivered in a pharmaceutically acceptable carrier as described herein below. The term antagonist or antagonizing is used in its broadest sense.
Antagonism can include any mechanism or treatment which results in inhibition, inactivation, blocking or reduction . 25 in gene activity or gene product. It should be noted that the inhibition of a gene or gene product can provide for an increase in a corresponding function that the gene or gene product was regulating. The antagonizing step can include blocking cellular receptors for the gene products and can include antisense treatment as discussed herein below. For example, a patient can be in need of inducing apoptosis in tumorogenic cells or angiogenesis in trauma situations where for example a limb must be reattached or in a transplant where revascularization is needed.
Many reviews have covered the main aspects of
C-12 - nn antisense (AS) technology and its enormous therapeutic potential (Wright and Anazodo, 1995). There are reviews on the chemical (Crooke, 1995; Uhlmann et al, 1990), cellular (Wagner, 1994) and therapeutic (Hanania, et al, 1995; Scanlon, et al, 1995; Gewirtz, 1993) aspects of this rapidly developing technology. Within a relatively short time, ample information has accumulated about the in vitro use of AS nucleotide sequences in cultured primary cells and cell lines as well as for in vivo administration of such nucleotide sequences for suppressing specific processes and changing body functions in a transient manner. Further, enough experience is now available in vitro and in vivo in animal models and human clinical trials to predict human efficacy.
Antisense intervention in the expression of specific genes can be achieved by the use of synthetic AS oligonucleotide sequences (for recent reports see
Lefebvre-d'Hellencourt et al, 1995; Agrawal, 1996; Lev-
Lehman et al, 1997). AS oligonucleotide sequences can be short sequences of DNA, typically 15-30 mer but can be as small as 7 mer (Wagner et al, 1996), designed to complement a target mRNA of interest and form an RNA:AS duplex. This duplex formation can prevent processing, splicing, transport or translation of the relevant mRNA.
Moreover, certain AS nucleotide sequences can elicit cellular RNase H activity when hybridized with their target mRNA, resulting in mRNA degradation (Calabretta et al, 1996). In that case, RNase H will cleave the RNA component of the duplex and can potentially release the AS to further hybridize with additional molecules of the target RNA. An additional mode of action results from the interaction of AS with genomic DNA to form a triple helix which can be transcriptionally inactive.
The sequence target segment for the antisense oligonucleotide is selected such that the sequence exhibits suitable energy related characteristics important for oligonucleotide duplex formation with their oo 5 complementary templates, and shows a low potential for self-dimerization or self-complementation [Anazodo et al., 1996] . For example, the computer program OLIGO (Primer
Analysis Software, Version 3.4), can be used to determine antisense sequence melting temperature, free energy properties, and to estimate potential self-dimer formation and self-complimentary properties. The program allows the determination of a qualitative estimation of these two parameters (potential self-dimer formation and self- complimentary) and provides an indication of "no potential" or "some potential" or "essentially complete potential™. Using this program target segments are generally selected that have estimates of no potential in these parameters. However, segments can be used that have "some potential" in one of the categories. A balance of the parameters is used in the selection as is known in the art. Further, the oligonucleotides are also selected as needed so that analogue substitution do not substantially affect function.
Phosphorothioate antisense oligonucleotides do not normally show significant toxicity at concentrations that are effective and exhibit sufficient pharmacodynamic half-lives in animals (Agarwal et al., 1996) and are nuclease resistant. Antisense induced loss-of-function phenotypes related with cellular development were shown for the glial fibrillary acidic protein (GFAP), for the establishment of tectal plate formation in chick (Galileo et al., 1991) and for the N-myc protein, responsible for the maintenance of cellular heterogeneity in neuroectodermal cultures (epithelial vs. neuroblastic
CC - 14 - i J ——
cells, which differ in their colony forming abilities, tumorogenicity and adherence) (Rosolen et al., 1990;
Whitesell et al, 1991). Antisense oligonucleotide inhibition of basic fibroblast growth factor (bFgF), oo 5 having mitogenic and angiogenic properties, suppressed 80% of growth in glioma cells (Morrison, 1991) in a saturable and specific manner. Being hydrophobic, antisense oligonucleotides interact well with phospholipid membranes (Akhter et al., 1991). Following their interaction with the cellular plasma membrane, they are actively (or passively) transported into living cells (Loke et al., 1989), in a saturable mechanism predicted to involve specific receptors (Yakubov et al., 1989).
Instead of an antisense sequence as discussed herein above, ribozymes can be utilized. This is particularly necessary in cases where antisense therapy is limited by stoichiometric considerations (Sarver et al., 1990, Gene Regulation and Aids, pp. 305-325). Ribozymes can then be used that will target the same sequence.
Ribozymes are RNA molecules that possess RNA catalytic ability (see Cech for review) that cleave a specific site in a target RNA. The number of RNA molecules that are cleaved by a ribozyme is greater than the number predicted by stochiochemistry. (Hampel and Tritz, 1989; Uhlenbeck, 1987).
Ribozymes catalyze the phosphodiester bond cleavage of RNA. Several ribozyme structural families have been identified including Group I introns, RNase P, the hepatitis delta virus ribozyme, hammerhead ribozymes and the hairpin ribozyme originally derived from the negative strand of the tobacco ringspot virus satellite
RNA (sTRSV) (Sullivan, 1994; U.S. Patent No. 5,225,347, columns 4-5). The latter two families are derived from viroids and virusoids, in which the ribozyme is believed to separate monomers from oligomers created during rolling circle replication (Symons, 1989 and 1992). Hammerhead and hairpin ribozyme motifs are most commonly adapted for trans-cleavage of mRNAs for gene therapy (Sullivan, 1994).
The ribozyme type utilized in the present invention is selected as is known in the art. Hairpin ribozymes are now in clinical trial and are the preferred type. In general the ribozyme is from 30-100 nucleotides in length.
Modifications or analogues of nucleotides can be introduced to improve the therapeutic properties of the nucleotides. Improved properties include increased nuclease resistance and/or increased ability to permeate cell membranes.
Nuclease resistance, where needed, is provided by any method known in the art that does not interfere with biological activity of the antisense oligodeoxy- nucleotides, cDNA and/or ribozymes as needed for the method of use and delivery (Iyer et al., 1990; Eckstein, 1985; Spitzer and Eckstein, 1988; Woolf et al., 1990; Shaw et al., 1991). Modifications that can be made to oligonucleotides in order to enhance nuclease resistance include modifying the phosphorous or oxygen heteroatom in the phosphate backbone. These include preparing methyl phosphonates, phosphorothioates, phosphorodithicates and morpholino oligomers. In one embodiment it is provided by having phosphorothioate bonds linking between the four to six 3'-terminus nucleotide bases. Alternatively, phosphorothioate bonds link all the nucleotide bases.
Other modifications known in the art can be used where the biological activity is retained, but the stability to nucleases is substantially increased.
The present invention also includes all analogues of, or modifications to, an oligonucleotide: of the invention that does not substantially affect the function of the oligonucleotide. The nucleotides can be selected from naturally occurring or synthetic modified bases. Naturally occurring bases include adenine, guanine, cytosine, thymine and uracil. Modified bases of the oligonucleotides include xanthine, hypoxanthine, 2- aminoadenine, 6-methyl, 2-propyl and other alkyl adenines,
S-halo uracil, 5-halo cytosine, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiuracil, 8-halo adenine, 8- aminoadenine, 8-thiol adenine, 8-thiolalkyl adenines, 8- hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8 -hydroxyl guanine and other substituted guanines, other aza and deaza adenines, other aza and deaza guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.
In addition, analogues of nucleotides can be prepared wherein the structure of the nucleotide is fundamentally altered and that are better suited as therapeutic or experimental reagents. An example of a nucleotide analogue is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in
DNA (or RNAO is replaced with a polyamide backbone which is similar to that found in peptides. PNA analogues have been shown to be resistant to degradation by enzymes and to have extended lives in vivo and in vitro. Further, + 25 PNAs have been shown to bind stronger to a complementary
DNA sequence than a DNA molecule. This observation is attributed to the lack of charge repulsion between the PNA strand and the DNA strand. Other modifications that can be made to oligonucleotides include polymer backbones, cyclic backbones, or acyclic backbones.
The active ingredients of the pharmaceutical composition can include oligonucleotides that are nuclease resistant needed for the practice of the invention or a fragment thereof shown to have the same effect targeted against the appropriate sequence(s) and/or ribozymes.
Combinations of active ingredients as disclosed in the present invention can be used including combinations of antisense sequences.
The antisense oligonucleotides = (and/or TT ribozymes) and cDNA of the present invention can be synthesized by any method known in the art for ribonucleic : or deoxyribonucleic nucleotides. For example, an Applied
Biosystems 380B DNA synthesizer can be used. When fragments are used, two or more such sequences can be synthesized and linked together for use in the present invention.
The nucleotide sequences of the present invention can be delivered either directly or with viral
R 15 or non-viral vectors. When delivered directly the sequences are generally rendered nuclease resistant.
Alternatively, the sequences can be incorporated into expression cassettes or constructs such that the sequence is expressed in the cell as discussed herein below.
Generally, the construct contains the proper regulatory sequence or promoter to allow the sequence to be expressed in the targeted cell.
Negative dominant peptide refers to a partial cDNA sequence that encodes for a part of a protein, i.e. a peptide (see Herskowitz, 1987). This peptide can have a different function from the protein it was derived from.
It can interact with the full protein and inhibit its activity or it can interact with other proteins and inhibit their activity in response to the full protein.
Negative dominant means that the peptide is able to overcome the natural proteins and fully inhibit their activity to give the cell a different characteristics like resistance or sensitization to killing. For therapeutic intervention either the peptide itself is delivered as the active ingredient of a pharmaceutical composition or the cDNA can be delivered to the cell utilizing the same methods as for antisense delivery.
By gene therapy as used herein refers to the transfer of genetic material (e.g. DNA or RNA) of interest into a host to treat or prevent a genetic or acquired disease or condition phenotype. The genetic material of interest encodes a product (e.g. a protein, polypeptide, peptide, functional RNA, antisense) whose production in vivo is desired. For example, the genetic material of interest can encode a hormone, receptor, enzyme, polypeptide or peptide of therapeutic value.
Alternatively, the genetic material of interest encodes a suicide gene. For a review see, in general, the text "Gene Therapy" (Advances in Pharmacology 40, Academic
Press, 1997).
Two basic approaches to gene therapy have evolved: (1) ex vivo and (2) in vivo gene therapy. In ex vivo gene therapy cells are removed from a patient, and while being cultured are treated in vitro. Generally, a functional replacement gene is introduced into the cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host /patient. These genetically reimplanted cells have been shown to express the transfected genetic material in situ.
In in vivo gene therapy, target cells are not removed from the subject rather the genetic material to be transferred is introduced into the cells of the recipient organism in situ, that is within the recipient. In an alternative embodiment, if the host gene is defective, the gene is repaired in situ (Culver, 1998]. These genetically altered cells have been shown to express the transfected genetic material in situ. : ghd The gene expression vehicle is capable of i. delivery/transfer of heterologous nucleic acid into a host : 5 cell. The expression vehicle can include elements to oo control targeting, expression and transcription of the nucleic acid in a cell selective manner as is known in the . art. It should be noted that often the 5' UTR and/or 3' - UTR of the gene can be replaced by the 5' UTR and/or 3! : 10 UTR of the expression vehicle. Therefore as used herein the expression vehicle can, as needed, not include the 5 . UTR and/or 3' UTR of the actual gene to be transferred and only include the specific amino acid coding region.
The expression vehicle can include a promoter . 15 for controlling transcription of the heterologous material and can be either a constitutive or inducible promoter to allow selective transcription. Enhancers that can be - required to obtain necessary transcription levels can optionally be included. Enhancers are generally any non- translated DNA sequence which works contiguously with the coding sequence (in cis) to change the basal transcription level dictated by the promoter. The expression vehicle can also include a selection gene as described herein below. . 25 Vectors can be introduced into cells or tissues by any one of a variety of known methods within the art.
Such methods can be found generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold
Springs Harbor Laboratory, New York (1989, 1992), in
Ausubel et al., Current Protocols in Molecular Biology,
John Wiley and Sons, Baltimore, Maryland (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, MI (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor,
MI (1995), Vectors: A Survey of Molecular Cloning Vectors
\ . and Their Uses, Butterworths, Boston MA (1988) and Gilboa et al (1986) and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see United
States patent 4,866,042 for vectors involving the central nervous system and also United States patents 5,464,764 and 5,487,992 for positive-negative selection methods.
Introduction of nucleic acids by infection offers several advantages over the other listed methods.
Higher efficiency can be obtained due to their infectious nature. Moreover, viruses are very specialized and typically infect and propagate in specific cell types.
Thus, their natural specificity can be used to target the vectors to specific cell types in vivo or within a tissue or mixed culture of cells. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through receptor mediated events.
A specific example of DNA viral vector for introducing and expressing recombinant sequences is the adenovirus derived vector AdenopS3TK. This vector expresses a herpes virus thymidine kinase (TK) gene for ~ either positive or negative selection and an expression cassette for desired recombinant sequences. This vector can be used to infect cells that have an adenovirus + 25 receptor which includes most cancers of epithelial origin as well as others. This vector as well as others that exhibit similar desired functions can be used to treat a mixed population of cells and can include, for example, an in vitro or ex vivo culture of cells, a tissue or a human subject.
Additional features can be added to the vector to ensure its safety and/or enhance its therapeutic efficacy. Such features include, for example, markers that can be used to negatively select against cells infected fs " with the recombinant virus. An example of such a negative selection marker is the TK gene described above that confers sensitivity to the antibiotic gancyclovir.
Negative selection is therefore a means by which infection - 5 can be controlled because it provides inducible suicide BN through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce altered forms of the viral vector or recombinant sequence, - cellular transformation will not occur.
Features that limit expression to particular cell types can also be included. Such features include, for example, promoter and regulatory elements that are specific for the desired cell type. . In addition, recombinant viral vectors are useful for in vivo expression of a desired nucleic acid ~ because they offer advantages such as lateral infection - and targeting specificity. Lateral infection is inherent cee in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells.
The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
As described above, viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms. Typically, viruses infect and propagate in specific cell types. The targeting specificity of viral vectors utilizes its natural
. v specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell. The vector to be used in the methods of the invention will depend on desired cell type to be targeted and will be known to those skilled in the art.
For example, if breast cancer is to be treated then a vector specific for such epithelial cells would be used.
Likewise, if diseases or pathological conditions of the hematopoietic system are to be treated, then a viral vector that 1s specific for blood cells and their precursors, preferably for the specific type of hematopoietic cell, would be used.
Retroviral vectors can be constructed to function either as infectious particles or to undergo only a single initial round of infection. In the former case, the genome of the virus is modified so that it maintains all the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and
RNA. Once these molecules are synthesized, the host cell packages the RNA into new viral particles which are capable of undergoing further rounds of infection. The vector's genome is also engineered to encode and express the desired recombinant gene. In the case of non- infectious viral vectors, the vector genome is usually mutated to destroy the viral packaging signal that is required to encapsulate the RNA into viral particles.
Without such a signal, any particles that are formed will not contain a genome and therefore cannot proceed through subsequent rounds of infection. The specific type of vector will depend upon the intended application. The actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology.
The recombinant vector can be administered in several ways. If viral vectors are used, for example, the w x procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site. However, local administration can . : provide a quicker and more effective treatment, . 5 administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. . Injection of the viral vectors into a spinal fluid can i. also be used as a mode of administration, especially in the case of neuro-degenerative diseases. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection.
DNA can also be administered using a gene gun. (Ziao & Brancksman, Nuceic Acids, Res. 24, 2630-2622 . 15 (1996) ) . The DNA is precipitated onto the surface of . microscopic metal beads. The microprojectiles are accelerated with a shock wave or expanding helium gas, and = penetrate tissues to a depth of several cell layers. For example, the Acal™ Gene Delivery Device manufactured by
Aegacetus, Inc., Middleton, WI, is suitable.
Alternatively, nucleic DNA can pass through skin into the bloodstream simply by spotting the DNA onto skin with chemical or mechanical irritation (see WO 95/05853).
An alternate mode of administration can be by + 25 direct inoculation locally at the site of the disease or pathological condition or by inoculation into the vascular system supplying the site with nutrients or into the : spinal fluid. Local administration is advantageous because there is no dilution effect and, therefore, a smaller dose is required to achieve expression in a majority of the targeted cells. Additionally, local inoculation can alleviate the targeting requirement required with other forms of administration since a vector can be used that infects all cells in the inoculated area.
If expression is desired in only a specific subset of cells within the inoculated area, then promoter and regulatory elements that are specific for the desired subset can be used to accomplish this goal. Such non- targeting vectors can be, for example, viral vectors, viral genome, plasmids, phagemids and the like.
Transfection vehicles such as liposomes can also be used to introduce the non-viral vectors described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art.
The pharmaceutical compositions containing the active ingredients of the present invention as described herein above are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the medical arts. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and . 25 other indicators as are selected as appropriate measures by those skilled in the medical arts. The pharmaceutical compositions can be combinations of the active ingredients but will include at least one active ingredient.
In the method of the present invention, the pharmaceutical compositions of the present invention can be administered in various ways taking into account the nature of compounds in the pharmaceutical compositions. It should be noted that they can be administered as the compound or as pharmaceutically acceptable salt and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds can be administered orally, subcutaneously or parenterally . : including intravenous, intra-arterial, intramuscular, g 5 intra-peritoneally, and intra-nasal administration as well as intra-thecal and infusion techniques. Implants of the . compounds are also useful. The patient being treated is a . warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, diluents, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.
It is noted that humans are treated generally longer than the mice or other experimental animals exemplified herein which treatment has a length proportional to the length of the disease process and drug effectiveness. The doses can be single doses or multiple doses over a period of several days, but single doses are preferred.
The doses can be single doses or multiple doses over a period of several days. The treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species . 25 being treated.
When administering the compound of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion) . The pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like),
suitable mixtures thereof, and vegetable oils.
Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Non-aqueous vehicles such a cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, can also be used as solvent systems for compound compositions. Additionally, various additives which enhance the stability, sterility, and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.
Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired.
A pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; ox the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies,
J : vectored delivery, iontophoretic, polymer matrices, . : liposomes, and microspheres. Examples of delivery systems g 5 useful in the present invention include: 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; - 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. ‘Many other such implants, delivery systems, and modules are well-known to those skilled in the art.
A pharmacological formulation of the compound utilized in the present invention can be administered orally to the patient. Conventional methods such as administering the compounds in tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the + 15 like are usable. Known techniques which deliver it orally : or intravenously and retain the biological activity are : preferred. . In one embodiment, the compound of the present invention can be administered initially by intravenous injection to bring blood levels to a suitable level. The patient's levels are then maintained by an oral dosage form, although other forms of administration, dependent upon the patient's condition and as indicated above, can be used. The quantity to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 pg/kg to 10 mg/kg per day.
The present invention also provides a method of diagnosing the presence of ischemia in a patient including the steps of analyzing a bodily fluid or tissue sample from the patient for the presence or gene product of at least one expressed gene (up-regulated) or their proteins and where ischemia is determined if the up-regulated gene or gene product is ascertained as described herein in the
. s
Example. The bodily fluids can include tears, serum, urine, sweat or other bodily fluid where secreted proteins from the tissue that is undergoing an ischemic event can be localized. Additional methods for identification of the gene or gene product are immunoassays, such as and ELISA or radioimmunoassays (RIA), can be used as are known to those in the art particularly to identify gene products in the samples. Immunohistochemical staining of tissue samples is also utilized for identification. Available immunoassays are extensively described in the patent and scientific literature. See, for example, United States patents 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521. Further for identification of the gene, in situ hybridization, Southern blotting, single strand conformational polymorphism, restriction endonuclease fingerprinting (REF), PCR amplification and
DNA-chip analysis using nucleic acid sequence of the present invention as primers can be used.
The above discussion provides a factual basis for the use of the sequences of the present invention to identify hypoxia-regulated genes and provide diagnostic probes to identify ischemia. The methods used with and the utility of the present invention can be shown by the non-limiting examples herein.
GENERAL METHODS
Most of the techniques used in molecular biology are widely practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs can serve as a
® , guideline. : General methods in molecular biology: Standard molecular biology techniques known in the art and not specifically described were generally followed as in
Sambrook et al., Molecular Cloning: A Laboratory Manual,
Cold Springs Harbor Laboratory, New York (1989), and in
Ausubel et al., Current Protocols in Molecular Biology,
John Wiley and Sons, Baltimore, Maryland (1989) particularly for the Northern Analysis and In Situ analysis and in Perbal, A Practical Guide to Molecular
Cloning, John Wiley & Sons, New York (1988), and in Watson et al., Recombinant DNA, Scientific American Books, New
York. Polymerase chain reaction (PCR) was carried out ) generally as in PCR Protocols: A Guide To Methods And
Applications, Academic Press, San Diego, CA (1990).
Reactions and manipulations involving other . nucleic acid techniques, unless stated otherwise, were performed as generally described in Sambrook et al., 1989,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, and methodology as set forth in United
States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference.
Additionally, in situ (In cell) PCR in combination with flow cytometry can be used for detection of «cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822).
General methods in immunology: Standard methods in immunology known in the art and not specifically described are generally followed as in Stites et al. (eds),
Basic and Clinical Immunology (8th Edition), Appleton &
Lange, Norwalk, CT (1994) and Mishell and Shiigi (eds),
Selected Methods in Cellular Immunology, W.H. Freeman and
Co., New York (1980). Available immunoassays are
. L extensively described in the patent and scientific literature. See, for example, United States patents 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521 as well as Sambrook et al, Molecular Cloning: A
Laboratory Manual, Cold Springs Harbor, New York, 1989.
The general methods of the invention are generally as described in US patent application serial number USSN 09/309,862 of same applicant which is by reference incorporated herein in its entirety.
In brief, USSN 09/309,862 provides methods for identifying genes regulated at the RNA level by cue- induced gene expression. It relates to the rapid isolation of differentially expressed or developmentally regulated gene sequences through analysis of mRNAs obtained from specific cellular compartments and comparing the changes in the relative abundance of the mRNA in these compartments as a result of applying a cue to the tested biological samples. The cellular compartments include © 25 polysomal and nonpolysomal fractions, nuclear fractions, cytoplasmic fractions and splicesomal fractions. The method includes the steps of exposing cells or tissue to a cue or stimulus such as mechanical, chemical, toxic, pharmaceutical or other stress, hormones, physiological disorders or disease; fractionating the cells into compartments such as polysomes, nuclei, cytoplasm and splicesomes; extracting the mRNA from these fractions, and subjecting the mRNA to differential analysis using accepted methodologies, such as gene expression array
Rd ’. (GEM) . : The method is designed for identifying and cloning genes which are either up- or down-regulated : : responsive to a specific pathology, stress, physiological condition, and so on, and in general, to any factor that can influence cells or organisms to alter their gene expression.
Further in USSN 09/309,862, an example is provided which shows the use of RNA isolation from nuclei for isolating genes whose steady state levels show only minor changes, but which show high differential expression when detected by nuclear RNA probe. Most such genes are regulated at the transcriptional level. . The specific mRNA of the invention is total cellular mRNA, and regulation is specifically on the transcriptional level.
DNA Microarrays
Preparation of custom hypoxia-specific microarrays
The cell system consisted of the C6 or Al72 glioma cell lines. The cells were exposed to hypoxia for 4 or 16 hours and compared to cells grown under normal conditions.
Subtracted libraries were made from the . 25 following sample: 1. 16 hours hypoxia vs. normal (genes induced by hypoxia after 16 hours). 2. Normal vs. 16 hours hypoxia (genes reduced by hypoxia) . 3. 4 hours hypoxia vs. normal (genes induced by hypoxia after four hours).
Three enriched libraries from the three groups above were made by the SSH method using the "PCR select
, N cDNA subtraction kit" from Clontech. From library 1, 1,000 colonies were grown and the plasmids prepared in 96 well format. From libraries 2 and 3, 500 colonies were processed from each. Thus, a total of 2,000 individual plasmids were prepared and used for the fabrication of a
Gene Expression Microarray (GEM). For this, the inserts of each plasmid were amplified by PCR and robotically fabricated on the glass.
Preparation of probes for microarray hybridization
Isolated messenger RNA is labeled with fluorescent dNTP's using a reverse transcription reaction to generate a labeled cDNA probe. mRNA is extracted from either C6 or A172 cells cultured in normoxia conditions and labeled with Cy3-dCTP (Amersham) and mRNA extracted from C6 or Al72 cells cultured under hypoxia conditions is labeled with Cy5-dCTP (Amersham). The two labeled cDNA probes are then mixed and hybridized onto microarrays (Schena et al, 1996) . Following hybridization the microarray is scanned using a laser scanner and the amount of fluorescence of each of the fluorescence dyes is measured for each cDNA clone on the micro-array giving an indication of the level of mRNA in each of the original mRNA populations being tested. Comparison of the . 25 fluorescence on each cDNA clone on the micro-array between the two different fluorescent dyes is a measure for the differential expression of the indicated genes between the two experimental conditions.
The following probes were made from C6 and A172 for screening the GEM: 1. Normoxia (Cy3 labeled ) + 16 hours hypoxia (Cy5 labeled) .
» . : 2. Normoxia (Cy3 labeled) + 4 hours hypoxia (Cy5 ~ labeled).
The following cDNA sequences were found to be induced under hypoxia conditions. The sequences are divided into three categories: 1. new genes; 2. known genes not known before this publication to be hypoxia- inducible; and 3. known genes known to be induced under hypoxia conditions.
In Situ Analysis:
In situ analysis is performed for the candidate genes identified by the differential response to exposure to hypoxia conditions as described above. The expression is studied in normal tissues and in pathological models as
B described herein.
Utilizing microarray hybridization the sequences - set forth herein were identified and cloned as being differentially expressed under hypoxia conditions (see also Braren et al, 1997).
In parallel experiments Northern Analysis results and results obtained by the gene expression microarray analysis where found to coincide and either can be used to determine hypoxia-regulated response. As well in other experiments, the results from in situ analysis showed a high degree of correlation with the Northern
Analysis and microarray analysis.
The sequences are listed that were found, the sequences are identified by clone number. In some cases either end of the clone has been sequenced for use or the entire clone sequence and protein sequence are provided.
Unigeml (Syntheni) was utilized for screening of human glioma cell line A172 to identify genes whose expression is modified by hypoxia.
v
A Retinopathy Model:
Three major biological processes occur in nervous tissues under hypoxic conditions: 1. apoptotic death of hypoxia-damaged cells; 2. angiogenesis induced by factors secreted by hypoxia- suffering cells (a feedback control of oxygen concentration in tissue); and 3. secretion of neurotrophic and neuroprotective factors.
Therefore, it was assumed that among novel genes transcriptionally regulated by hypoxia in C6 and A172 glioma cells, there are those with pro- and antiapoptotic function as well as secreted neurotrophic, neuroprotective and angiogenic factors. It is worth noting, that regulation of apoptosis and angiogenesis is closely linked to cancerogenesis.
As initial step of biological characterization, candidate genes were tested for their ability to induce/protect cells from apoptosis, for neurotrophic activity and for angiogenic/antiangiogenic activity.
The sequences of the invention, the methods used therewith and the utility of the present invention can be shown by the following non-limiting examples:
EXAMPLE 1: 32 (SEQ ID. No.: 1)
Northern Blot Analysis:
Gene 92 is found upregulated after 16 hours of hypoxia. On Northern blots, it appears as a single 5 Kb transcript.
» x
Cloning: - Several partial human cDNA clones corresponding to gene 92 were isolated from human A172 cDNA library. The length of available contig is 2212 bp and it contains an
ORF potentially coding for a 437 amino acids (265-1576 bp) protein. The putative initiating ATG codon is preceded by in frame stop codon.
Bioinformatic Analysis:
Similarity search with 92 ¢DNA sequence against the public databases have shown 60% similarity to unknown
Drosophila DNA sequence (AC004283) and mainly encompasses the 3' UTR and a part of the coding sequence. The search against the protein public databases gave partial similarity to hypothetical C. elegans protein (1703624) (77% similarity and 46% Identity).
The 92 cDNA sequence contains a region of 55 nucleotides (336-390 bp) that is constituted of CCGG repeats. On the level of amino acids it appears as a
GGD/SFGG repeated unit (aa 24-44). Two of the isolated cDNA clones contain a 30 nucleotides in frame deletion within this region, indicating that the amount of repeats can be variable. 44 of these nucleotides form a strong . 25 stem and loop secondary structure. When 92 cDNA was in vitro translated, the obtained protein had much smaller size than expected (30 kD instead of 45 kD). This, means that the stem and loop structure formed right downstream to the putative initiation codon prevents the proper progression of ribosome and the initiation actually starts from the next in frame ATG located at position 820 - 822.
EXAMPLE 2: 95 (SEQ ID. No.: 2)
Northern Blot Analysis:
Expression of this gene is upregulated by hypoxia. In normoxic conditions it appears as a single moderately expressed 3.9 Kb transcript. After four hours of hypoxia, an additional transcript of 4.3 Kb becomes evident. After 16 hours of hypoxia, an increase in the amount of the major 3.9 Kb transcript takes place and there appears the second additional transcript 4.5 Xb in size.
Cloning:
A complete human 95 cDNA clone, corresponding to the major 3.9 Kb mRNA was isolated. The contig is 3,535 bp long and it potentially codes for a 480 aa (ORF: nt 323- 1763) protein. All the attempts to clone the gene 95 splice variants had thus far failed, although numerous different approaches were employed.
Bioinformatic And Literature Analysis:
Search against public databases revealed that gene 95 is similar to but not identical with a recently cloned human P53-responsive gene PA26 that codes for a nuclear protein (Oncogene, 18, 127 - 137, 1999). Like gene 95, the PA26 one is expressed in three splice variants.
The major transcript is 2.6 Kb in size (T2) and is ubiquitously expressed, the second transcript is 74 Kb (T1) and displays a certain tissue specificity of expression pattern. The third transcript is approximately 2.3 Kb (T3) and is very minor. Expression of 2.6 and 2.3
Kb transcripts is p53-regulated and is increased in response to irradiation, UV, doxorubicin etc. The 4 Kb transcript 1s not induced by p53. The PA26-specific transcripts share a set of C-terminal common exons, while the first exon is individual for each splice form. Gene 95 encoded putative protein shares the maximal amino acid homology with the common region of PA26-specific proteins. : In its N-terminus, the putative protein 95 mostly . resembles the T2 (major pS53-inducible variant) variant of ’ 5 PA26.
PA26, maps to chromosome 6g2l1. Biologically it shares properties common to the GADD family of Growth
Arrest and DNA Damage-inducible stress-response genes.
Domain Analysis:
A short sequence with features of second paroxysmal targeting signal was found in protein 95 between amino acids 353-361. A putative coiled coil region is found between amino acid positions 253-283.
Further Analysis Of Gene 95 Expression Pattern:
By analogy with gene PA26, it was assumed that alternative splicing in gene 95 also occurs in the first exons. To identify the mRNA species where the cDNA clone was derived from, two 95-specific probes were synthesized: (1) corresponding to the region homologous to the first exon of PA26 transcript T2 (Probe 1), and (2) corresponding to the region homologous to a common set of
PA26 exons (but encompassing the sequences that are mostly diverged between the two genes) (Probe 2). On Northern blots, both probes recognized the same major 3.9 Kb 95- specific transcript that is up-regulated by hypoxia. No additional transcripts were identified by Probe 2. The 95- specific probe that was used for the initial set of hybridizations did not recognize any additional transcripts when hybridized to this newly prepared
Northern blot. Therefore, the occurrence of 95-specific additional mRNA species seem to vary among different mRNA preparations.
The sizes of PA26 and (gene 95 encoded transcripts are different. However, in order to exclude the possibility that the presence of alternative 95 RNA species stem from cross-hybridization, a PA26 specific cDNA probe was synthesized originating from the common exons region. On the Northern blot used for the previous experiment, the PA26 hybridized to two typical mRNA species of 2.6 and 4 Kb. Their levels, unlike the level of 95 mRNA, were not affected by hypoxia.
There is contradictory data in the literature about the nature of p53 protein present in A172 cells: according to some sources, it is wild type, according to others, mutated. The experiments performed thus far, conclude that hypoxia-induced expression of gene 95 is pb53-independent.
The mammalian 95 expression vector was prepared and effects of this gene overexpression in mammalian cells were studied.
Summary: 95 is a novel hypoxia-induced human gene coding for a protein similar to p53-induced GADD protein PA26.
However, the latter is inert to hypoxia stimulation.
Therefore, there appears to exist two closely related proteins encoded by different genes that are upregulated by different genotoxic stresses. Protein 95 contributes to hypoxia-induced growth regulation in a way similar to
PA26, but in a p53 independent manner. It is known that hypoxia-induced growth arrest that can take place in the core regions of p53-negative tumors is one of the obstacles for success of full chemotherapy. Therefore, inactivation of gene 95 can be a potent adjuvant for chemotherapeutic treatment of cancers.
EXAMPLE 3: 98 (SEQ. ID. No.: 3) . : Northern Blot Analysis:
Expression of gene 98 is strongly up-regulated by hypoxia already after four hours of exposure. On
Northern blots, it appears as a single mRNA species of 4.4. Kb.
Cloning:
A full-length 98 cDNA was cloned. It is 4138 bp long and contains an single ORF encompassing the nucleotides 204 - 1445. The putative protein is 414 amino acid a long.
Bioinformatic Analysis: - Search of the public databases revealed that 98 encoded protein is similar to two other human proteins: (1) a putative protein encoded by anonymous human 24945 mRNA sequence (AF131826) and (2) VDUP1l (protein induced in
HL-60 cells by dihydroxy vitamin D3 treatment) (S73591).
No significant structural features were found by existing protein analysis tools within the 98 putative protein.
It was previously demonstrated that treatment with vitamin D3 can induce apoptosis in C6 rat glioma cells (J. Neurosci Res,46, 540 - 550). Therefore, the relationship between the vitamin D-induced cell killing and 98 gene expression and function in glioma cells was studied.
The mammalian 98 expression vector was then and its effects studied.
EXAMPLE 4: 60F6 (SEQ. ID. No.: 4)
®
Northern Blot Analysis:
Expression of this gene is moderately up-regulated after 16 hours of hypoxia. On Northern blot, it appears as a single 3.0 Kb species.
Cloning:
A complete 60F6 human cDNA clone was isolated from
Al72 cDNA library. The contig is 2675 bp long and contains a single ORF (bp 134 - 866) able to code for a putative protein of 244 amino acids.
Bioinformatic Analysis:
A similarity search against the public databases revealed that the N-terminal half of 60F6 sequence exactly corresponds to a human cDNA coding for RhoE/Rho8 small. GTP- binding protein (P52199, HSRHO8GRN) . The identity of gene 60F6 was not determined before, because the small sequenced fragment that was initially possessed, originated from the Rho8 long 3°
UTR. All the sequence information available in public databases did not include the long 3’ UTR of Rhos. Structurally, Rho$s belongs to a family of Ras- related GTPases that regulate the actin cytoskeleton. However, this protein is unique in that it is constitutively active:
GTPase deficient and in vivo farnesylated (Mol Cell Biol. 1996 Jun; 16 (6) : 2689-99).
Therefore, it is intriguing to find that this constitutively active G-protein is regulated on the level of transcription.
Hypoxia regulation of Rho8 was not previously described.
EXAMPLE 5: 648 (lysyl hydroxylase 2) (SEQ.ID. Nos. :5-7).
Northern analysis
Probe 648 has detected a single 3.8 Kb 41 transcript on Northern blots. Expression was induced in C6 glioma cells already after 4 hours of hypoxia
Cloning
After extension of initial cDNA probe by RACE it became evident that identified rat sequence (Seg. I.D. No: 7); is able to code for protein that represents a rat homologue of human lysyl hydroxylase 2 (PLOD2). The full- length open reading frames was cloned for both human and rat lysyl hydroxylase 2 homologues (by PCR, using primers built on the basis of known sequence, for human variant, and degenerative primers, for rat variant). The encoded proteins have well defined signal peptides.
Bioinformatics data
The cloned rat 648 cDNA (Fig. 5C, Seqg.l1.D. No: 7); contains an ORF coding for a putative protein that is 88% identical to the published human PLOD2 sequence (Fig. 5A, Seg. I.D. No:5); The least conserved sequences are within the signal peptide, however its functional features are completely preserved. The cloned human cDNA (Fig. 5B,
Seq. I.D.No:6); is almost identical to published human
PLOD2 sequence. The word "almost" in the previous sentence stems from the fact that both in human and in rat cDNA species cloned in QBI a stretch of amino acids between positions 501- 521 of published sequence PLOD2 sequence was absent. Therefore, QBRI's PLOD2 variants are differentially spliced. Both rat and human homologues were amplified from RNA extracted from glioma cell lines cultured in hypoxic conditions.
Literature review
Lysyl hydroxylases are the enzymes that catalyze the formation of hydroxylysine in collagens and other proteins with collagen-like amino-acid sequences, by the hydroxylation of lysine residue in X-K-G sequences. The hydroxilysine residues have two important functions: (1) serve as sites of attachment of carbohydrate units, and (2) they are essential for the stability of the intermolecular collagen crosslinks. Congenital deficiency of 1lysyl hydroxylase in humans leads to increased solubility of collagens and, consequently, to numerous defects in organization of connective tissue in various organs. There are three known isoforms of lysyl hydroxilase, encoded by different genes. In humans, PLOD2 was found to be highly expressed in pancreas, skeletal muscle, heart and placenta (by Northern blot). Nothing is known either about the regulation of PLOD2 expression by hypoxia or about its involvement in angiogenesis and tumorigenesis. Induction of PLOD2 by hypoxia can probably account for hypoxia-induced tissue fibrosis. Indeed, specific lysyl hydroxylase inhibitor, minoxidil, was able to suppress both cellular collagen production and fibroblasts proliferation (J. Biol. Chem., 262, 11973 -8, 1987; Graefes Arch. Clin. Exp. Ophthalmol. 233, 347 -55, 1995). There were suggestions in literature to use modified 1lysyl hydroxylase inhibitor for treatment of vitreoretinopathy (Invest. Ophthalmol. Vis .Sci. 34, 567- 75, 1993).
Analysis of alternatively spliced versions of gene 648
In order to establish whether the observed alternative splicing of PLOD2 is regulated by hypoxia, a set of PCR primers were synthesized that flank the alternatively spliced region. The expected sizes of RT-PCR products are: 216 bp, for published sequence and 156 bp, for the present sequence. Semi-quantitative RT-PCR was performed on RNA template extracted from human glioma A172 cells culture in either normoxia or in hypoxia for 4 and 16 hours. The obtained results clearly demonstrate that both PLOD2 forms are hypoxia regulated, but the form of the invention appears only in hypoxic conditions.
Testing potential pro~ and antiapoptotic activity in : transient transfection assays : PcDNA3-648 was transiently co-transfected together with pcDNA3-GFP in Hela and 293 cells. 24 and 48 hours later the cells were fixed and stained with DAPI. No apoptotic effect was observed in the transfected cells. In order to evaluate the anti-apoptotic properties of the 648 protein, a co-transfection assay was conducted using the
PcDNA3-GFP and the FAS plasmids. No anti-apoptotic effect was observed.
Obtaining stable cell clones overexpressing 648 cDNA
C6 were stably transfected with 5 ug of the
PcDNA3-648 plasmid. Following G418 selection the level of expression was measured using Northern blot analysis in comparison to its level in C6 cells after 16 hours under hypoxic conditions. Out of 18 independent clones from the pcDNA3-648 transfection, no one was positive.
In situ hybridization analysis
Retinopathy model
Probe 648 demonstrates clear hybridization signal throughout the inner nuclear layer of "hypoxic" pup's retina while "normoxic" retina is negative for the expression. No hybridization signal was detected in adult retina.
In mouse embryo sections hybridization signal was detected in some apoptotic cells in the roof of the fourth brain ventricle and in developing retina ganglia, where expressing cells had no apoptotic features.
Multi-tissue block hybridization shows expression of 648 gene (rat PLOD2) in visceral smooth muscles in oviduct, uterus, stomach and intestine. Vascular smooth
9 do not display hybridization signal.
Most prominent cell type hybridizing to 648 probe in ovary are granulosa cells of larger secondary follicles. No hybridization signal is detected in granulosa cell of primary and small secondary follicles. Significantly, hybridization signal is weakened in postovulatory follicles and completely disappears in corpora lutea. This shows that expression in granulosa cells is established at later stages of follicular maturation and it is abruptly down-regulated upon ovulation and the onset of conversion into lutein cells. On the other hand, follicular involution is not accompanied by the changes in 648 expression since strong hybridization signal is preserved in granulosa cells of atretic follicles.
Weak hybridization signal can be seen in some stromal cells surrounding large secondary follicles and corpora lutea as well as in cells of theca internal of secondary follicles.
Prominent signal is found in "interstitial glands". This shows distinct regulation of 648 expression in theca cells undergoing "luteinization" in different locations: it is down regulated in corpora lutea but preserved or even unregulated in interstitial glands.
As to the germinal cells, an oocyte that expresses 648 was found only in one primary follicle while many other primary and secondary follicles had no hybridization signal. This shows a transient expression of 648 in oocytes at some stage of their development.
Discrepancy in the hybridization patterns of human (published) Seq.I.D. No: 5 and rat PLOD2 (648)Seq. I.D.No: 7; genes is explained by different sensitivities of different detection methods Northern blot vs. in situ hybridization).
The rat probe used in the present invention does not span an alternatively spliced region.
i ®
EXAMPLE 6: 24D4 (SEQ. ID. No : 8
Northern blot analysis
Expression of gene 24D4 is down-regulated after 16 hours of hypoxia. On Northern blots, it appears as a single 1.5 Kb mRNA species.
Cloning
A partial 24D4 human cDNA clone was isolated from
A172 cDNA library. The available sequence is 1486 bp long and contains an N-terminal truncated ORF (bp 1-397).
Bioinformatic analysis
The sequence has no analogs in public databases. - The available protein sequence contains three consequent
Zn-finget motifs, all of C2H2 type (aa 52-72, 80-100 and 108-128). Zinc finger domains of this type are usually found in nucleic acid-binding proteins.
EXAMPLE 7: 77H4 (SEQ. ID. No : 9-10)
Northern blot analysis
Expression of gene 77H4 is up-regulated after 16 hours of hypoxia. On Northern blots, it appears as a single mRNA species 0.6 -0.7 Kb in size.
Cloning
Several EST cDNA clones from public databases, corresponding to clone 77H4, were sequenced. All clones possess a poly A tail and a polyadenylation signal at their 3’ end.
Biocinformatic analysis
EST clone 18E (Seq. I.D. No: 9); contains 580 bp, that include an ORF for a 120 aa protein (bp 92 - 452) . The EST clone 3D (Seg. I.D. No: 10); contains 486 bp. Comparison of nucleotide sequences of clone 18E and 3D reveal that the latter has a out-of-frame deletion of 71 nucleotides between bp 279-339 of clone 18E (its putative coding region) (Figs.7A and 7B); This raised the question whether 77H4 cDNA is at all coding. The sequence was analyzed by Genscan program, that predicts the potential coding sequences on the basis of codon usage. The only potentially coding segment was found in clone 18E between bp 93 and 235. An exhaustive search was performed of public databases for all 77H4-related sequences. Several independent contigs were identified in TIGR THC database. All of them are not completely identical to one another and contain nucleotide deletions of various length. This shows a certain variability in 77H4 nucleotide sequence.
Recently, a novel steroid receptor transcriptional coactivator, SRA, was found to be present as an RNA molecule in the transcription activating complex SRC-1 (Cell, 97, 17 - 27, 1999) . Although no similarity was found between clone 77H4 and SRA RNA on the sequence level, several characteristic features seem to be shared by both sequences: -1l both mRNAs, 77H4 and SRA, are approximately of the same size 7.7 Kb; -2 sequencing multiple cDNA clones corresponding to either mRNA revealed extensive variability in certain regions; *3 hybridization signals of both mRNA, therefore, appear as fuzzy bands on Northern blots; 4 both mRNA do not exhibit characteristics of protein.
Therefore, the 77H4 cDNA clcne has similar to
SRA function and can serve a coactivator in some transcriptional complexes.
EXAMPLE 8: 14G2 (SEO. ID. No : 11) _ er Tac \oAY. SJ. No : 11)
Northern blot analysis
Expression of gene 14G2 is regulated within 16 hours of hypoxia. On Northern blots, it appears as a single mRNA species.
Cloning
A partial 14G2 human cDNA clone was isolated. The available sequence was then characterized and cloned as shown in Figure 8.
EXAMPLE 9: 29F3 (SEQ. ID. No : 12) _— nC 27” on. JD. No : 12)
Northern blot analysis
Expression of gene 29F3 is regulated within 16 hours of hypoxia. On Northern blots, it appears as a single mRNA species.
Cloning
A partial 29F3 human cDNA clone was isolated. The available sequence was then characterized and cloned as shown in Figure 9.
Throughout this application. various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this, application in order to more fully describe the state of the art to which this invention pertains.
The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.
Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the described invention, the invention can be practiced otherwise than as specifically described.
Alon, et al. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat
Med. 1(10):1024-1028.
Benjamin, et al. (1997). Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc
Natl Acad Sci USA. 94(16) :8761-8766.
Bouck, et al. (1996). How tumors become angiogenic. Adv.
Cancer Res. 69:135-174.
Braren et al. (1997). Use of the EST database resource to identify and clone novel mono (ADP-ribosyl)transferase gene family members. Adv. Exp. Med. Bio. 419:163-168.
Bunn, et al. (1996) . Oxygen sensing and molecular adaptation in hypoxia. Physiol Rev. 76:839-885.
Carmeliet, et al. (1998). Role of HIF-lalpha in hypoxia- mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394 (6692) :485-490.
Dor, et al. (1997). Ischemia-driven angiogenesis. Trends
Cardiovasc. Med. 7:289-294.
Duke, et al. (1996). Cell Suicide in Health and Disease.
Scientific American. 80-87. : Fyodorov, et al. (1998). Pet-1, a novel ETS domain factor that can activate neuronal nAchR gene transcription. J
Neurobiol. 34(2):151-163.
Gallagher et al., (1997). Identification of p53 Genetic
Suppresser Elements Which Confer Resistance to Cisplatin. 40 Oncogene 14:185-193.
Hanahan, et al. (1996). Patterns and Emerging Mechanisms of
Angiogenic Switch During Tumorigenesis. Cell. 86:353-364. 45 Obeso, et al. (1990). A Hemangiocendothelioma-Derived Cell.
Line: Its Use as a Model for the Study of Endothelial Cell
Biology. Laboratory Investigation. 83:259-264.
Okubo et al. (1997). Complementary DNA sequence (EST) collections and the expression information of the human genome. FEBS Lett 403:225-229.
Schena et al., (1996) Parallel Human Genome Analysis:
Microarray-based Expression Monitoring of 1000 genes. PNAS (USA) 93 (20) :10614-10619.
Spence, et al. (1998). Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C- lljglucose and FDG: analysis of the FDG lumped constant. J
Nucl Med. 39(3):440-448.
Watanabe, et al. (1996) . Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res. 56(13) :2960-2963.
Zweiger et al. (1997) From Expressed Sequence Tags to "epigenomics": An Understanding of Disease Processes. Curr
Opin Biotechnol 8 (6) :684-687.
Burke and Olson, "Preparation of (Clone Libraries in Yeast
Artificial-Chromosome Vectors" in Methods in Enzymology,
Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991).
Capecchi, "Altering the genome by homologous recombination”
Science 244:1288-1292 (1989).
Davies et al., "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer", Nucleic Acids
Research, Vol. 20, No. 11, pp. 2693-2698 (1992).
Dickinson et al., "High frequency gene targeting using insertional vectors", Human Molecular Genetics, Vol. 2, No. 8, pp. 1299-1302 (1993).
Duff and Lincoln, "Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene 40 and expression in ES cells", Research Advances in
Alzheimer's Disease and Related Disorders, 1995.
Huxley et al., "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by 45 cell fusion", Genomicg, 9:742-750 (1991).
Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature,
Vol. 362, pp. 255-261 (1993).
Lamb et al., "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29 (1993).
Pearson and Choi, Expression of the human f-amyloid precursor protein gene from a heast artificial chromosome in transgenic mice. Proc. Natl. Scad. Sci. USA, 1993. 90:10578-82.
Rothstein, "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast" in Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and
Molecular Biology", eds. C. Guthrie and G. Fink, Academic
Press, Inc., Chap. 19, pp. 281-301 (1991).
Schedl et al., "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261 (1993).
Strauss et al., "Germ line transmission of a yeast artificial chromosome spanning the murine a, (I) collagen locus", Science, Vol. 259, pp. 1904-1907 (1993).
Gilboa, E, Eglitis, MA, Kantoff, PW, Anderson, WF: Transfer and expression of cloned genes using retroviral vectors.
BioTechniques 4(6) :504-512, 1986.
Cregg JM, Vedvick TS, Raschke WC: Recent Advances in the
Expression of Foreign Genes in Pichia pastoris,
Bio/Technology 11:905-910, 1993
Culver, 1998. Site-Directed recombination for repair of mutations in the human ADA gene. (Abstract) Antisense DNA &
RNA based therapeutics, February, 1998, Coronado, CA. 40 Huston et al, 1991 "Protein engineering of single-chain Fv analogs and fusion proteins" in Methods in Enzymology (JJ
Langone, ed.; Academic Press, New York, NY) 203:46-88.
Johnson and Bird, 1991 "Construction of single-chain Fvb 45 derivatives of monoclonal antibodies and their production in Escherichia coli in Methods in Enzymology (JJ Langone, ed.; Academic Press, New York, NY) 203:88-99. - 52 - 0 _ I
Mernaugh and Mernaugh, 1995 "An overview of phage-displayed recombinant antibodies" in Molecular Methods In Plant
Pathology (RP Singh and US Singh, eds.; CRC Press Inc.,
Boca Raton, FL) pp. 359-365.
Agrawal, 1996. Antisense oligonucleotides: towards clinical trials, TIBTECH, 14:376.
Akhter et al, 1991. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nuc. Res. 19:5551-5559. ’ Blaesse, 1997. Gene Therapy for Cancer. Scientific
American 276(6):111-115.
Calabretta, et al, 1996. Antisense strategies in the treatment of leukemias. Semin. Oncol. 23:78.
Crooke, 1995. Progress in antisense therapeutics, Hematol.
Pathol. 2:59.
Felgner, 1997. Nonviral Strategeies for Gene Therapy.
Scientific American. June, 1997, pgs 102-106.
Gewirtz, 1993. Oligodeoxynucleotide-based therapeutics for human leukemias, Stem Cells Dayt. 11:96.
Hanania, et al 1995. Recent advances in the application of gene therapy to human disease. Am. J. Med. 99:537.
Lefebvre-d'Hellencourt et al, 1995. Immunomodulation by cytokine antisense oligonucleotides. Eur. Cytokine Netw. 6:7.
Lev-Lehman et al., 1997. Antisense Oligomers in vitro and in vivo. In Antisense Therapeutics, A. Cohen and 8S.
Smicek, eds (Plenum Press, New York)
Loke et al, 1989. Characterization of oligonucleotide 40 transport into living cells. PNAS USA 86:3474.
Morrison, 1991. Suppression of basic fibroblast growth factor expression by antisense oligonucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chen. 45 266:728.
Rosolen et al., 1990. Cancer Res. 50:6316.
Uhlmann and Peyman, 1990. Antisense Oligonucleotides: A
New Therapeutic Principle. Chem Rev 90(4) :543-584.
Wagner et al., 1996. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature
Biotechnology 14:840-844.
Wagner, 1994. Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333.
Whitesell et al., 1991. Episome-generated N-myc antisense
RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol. Cell. Biol. 11:1360.
Yakubov et al, 1989. PNAS USA 86:6454.
Wright & Anazodo, 1995. Antisense Molecules and Their
Potential For The Treatment Of Cancer and AIDS. Cancer J. 8:185-189.
Scanlon et al., 1995. Oligonucleotides-mediated modulation of mammalian gene expression. FASEB J. 9:1288.
Galileo et al., 19921. J. Cell. Biol., 112:1285.
Gewirtz, 1993. Oligodeoxynucleotide-based therapeutics for human leukemias, Stem Cells Dayt. 11:96.
Eckstein 1985. Nucleoside Phosphorothioates. Ann. Rev.
Biochem. 54:367-402.
Iyer et al. 1990. J. Org. Chem. 55:4693-4699.
Radhakrishnan et al., 1990. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-
Benzodithiol-3-0ne 1,1 Dioxide as a sulfur-transfer reagent. J. Org. Chem. 55:4693-4699.
Shaw et al., 1991. Modified deoxyoligonucleotides stable to 40 exonuclease degradation in serum. Nucleic Acids Res. 19:747-750.
Spitzer and Eckstein 1988. Inhibition of deoxynucleases by phosphorothioate groups in oligodeoxyribonucleotides. 45 Nucleic Acids Res. 18:11691-11704. :
Woolf et al., 1990. The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos.
Nucleic Acids Res. 18:1763-1769.
Cell, 97, 17 - 27, 1999
Claims (15)
1. A polynucleotide for use in identifying genes modulated by hypoxic conditions.
2. The polynucleotide according to claim 1, wherein said polynucleotide is selected from the group comprising nucleic acid sequence having SEQ. ID NOS. 1-9 and functional analogs thereof.
3. A diagnostic tool for identifying genes modulated by hypoxic conditions comprising detection means for detecting the presence of a polynucleotide having the acid sequence of SEQ. ID NOS. 1-9 and functional analogs thereof.
4. A pharmaceutical composition for modulating hypoxia and ischemia comprising an effective amount of a polynucleotide having the nucleic acid sequence according to SEQ. ID NOS. 1-9 and functional analogs thereof and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4, wherein said pharmaceutical composition is used for gene therapy.
. .
6. A pharmaceutical composition for modulating hypoxia and ischemia comprising an effective amount of a protein encoded by the nucleic acid sequence according to
SEQ. ID NOS. 1-9 and functional analogs thereof and a pharmaceutically acceptable carrier.
7. A method of diagnosing the presence of a hypoxia associated pathology by screening for the presence at least one polynucleotide having the nucleic acid sequence according to one from the group comprising SEQ. ID
NOS. 1-9 and functional analogs thereof.
8. A method of regulating hypoxic associated pathologies by administering an effective amount of a polynucleotide having a nucleic acid sequence from at least one from the group comprising SEQ. ID NOS. 1-9 and functional analogs thereof and a pharmaceutically acceptable carrier.
9. A method of regulating hypoxia associated pathologies by administering an effective amount of at least one antisense oligonucleotide against one of the nucleic acid sequences (SEQ. ID NOS. 1-9) or their proteins.
10. A method of regulating hypoxia associated pathologies by administering an effective amount of a protein encoded by the polynucleotide sequence from at least one of from the group comprising SEQ. ID NOS. 1-9 ang functional analogs thereof as active ingredients in ga pharmaceutically acceptable carrier. —_ 57 -
, » : “ .
11. A method of regulating hypoxia associated pathologies by administering an effective amount of a direct or indirect biologically active product of enzymatic activity of the protein encoded by the polynucleotide sequence from at least one of from the group comprising
SEQ. ID NOS. 1-9 and functional analogs thereof as active ingredients in a pharmaceutically acceptable carrier.
12. A method of regulating hypoxia associated pathologies by administering an effective amount of inhibitors of a direct or indirect biologically active product of enzymatic activity of the protein encoded by the polynucleotide sequence from at least one of from the group comprising SEQ. ID NOS. 1-9 and functional analogs thereof as active ingredients in a pharmaceutically acceptable carrier.
13. A method of regulating hypoxia associated pathologies by inhibiting the enzymatic activity of the protein encoded by the polynucleotide sequence from at least one of from the group comprising (SEQ. ID NOS. 1-9) and functional analogs thereof as active ingredients in a pharmaceutically acceptable carrier.
14. A hypoxia response regulating gene.
15. The hypoxia response regulating gene according to claim 14, wherein said gene having the nucleic acid sequence according to SEQ. ID NOS. 1-9 and functional analogs thereof.
, WO ofs2s PCT/IS09/26394 AMENDED CLAIMS [received by the International Bureau on 15 February 2000 (15.02.00); original claims 1-12 replaced by naw claims 1-12; : original claims 13-15 cancelled (2 pagss)] A A polynucleotide selected from the group consisting of SEQ ID Nos: 1-9, and functional analogs and complements thereof which is differentially expressed and/or modulated under hypoxic conditions, .
2. The polynucleotide according to claim 1 having hypoxia- regulating activity.
3. A diagnostic tool for identifying genes modulated by hypoxic : conditions comprising detection means for detecting the presence of the polynucleotide of claim 1 and functional analogs thereof, 4, A method of diagnosing the presence of a hypoxia-associated pathology by screening for the presence of the polynucleotide of claim 1 and functional analogs thereof. B
5. Use of the polynucleotide of claim 1 and functional analogs thereof .in the manufacture of a medicament for regulating hypoxia-associated pathologies.
6. Use of a protein encoded by the polynucleotide - of claim 1 and functional analogs thereof in the : manufacture of a medicament for regulating hypoxia- associated pathologies.
7. Use of a direct or indirect biolegically active product of enzymatic activity of a protein encoded by the polynucleotide sequence according to claim 1 functional analogs thereof in the manufacture of a medicament for regulating hypoxia-associated pathologies. -59- FURTHER AMENDED SHEET
WO of: PCT/US99/20384
8. Use of inhibitors of a direct or indirect biologically active product of enzymatic activity of a protein encoded by the polyncelectide sequence according to claim 1 and functional analogs thereof in the manufacture of a medicament for regulating hypoxia- associated pathologies. : :
9. Use of a product for inhibiting the enzymatic activity of a protein encoded by the polynucleotide sequence according to claim 1 and functional analogs thereof in regulating hypoxia-associated pathologies. :
10. A pharmaceutical composition for modulating hypoxia and ischemia comprising an effective amount of a polynucleotide according to - claim 1 and functional analogs thereof and a pharmaceutically acceptable camer. Ce EP oo To
11. The pharmaceutical composition according to claim 10, wherein said pharmaceutical composition is used for gene therapy. : 12. A pharmaceutical composition for modulating hypoxia and ischemia comprising a pharmaceutically effective amount of a protein encoded by the nucleic acid sequence according to SEQ ID NOS. 1-8 and functional analogs thereof and a pharmaceutically acceptable carrier. : ~60- FURTHER AMENDED SHEET
NEW CLAIMS {
13. Use of a polynucleotide in accordance with claim 1 as a diagnostic tool for diagnosing the presence of a hypoxia-associated pathology.
14. A polynucleotide of SEQ ID NO:2 or a functional analog or complement thereof.
15. A polynucleotide of SEQ ID NO:3 or a functional analog or complement thereof. * 16. The protein encoded by a polynucleotide of claim 14 or 15. RE Ee Ce eh _ ers oe C81 = : BO A AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9815898P | 1998-08-27 | 1998-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200101566B true ZA200101566B (en) | 2003-06-26 |
Family
ID=29709398
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200101566A ZA200101566B (en) | 1998-08-27 | 2001-02-26 | Sequences characteristic of hypoxia-regulated gene transcription. |
ZA200101567A ZA200101567B (en) | 1998-08-27 | 2001-02-26 | Hypoxia regulated genes. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200101567A ZA200101567B (en) | 1998-08-27 | 2001-02-26 | Hypoxia regulated genes. |
Country Status (1)
Country | Link |
---|---|
ZA (2) | ZA200101566B (en) |
-
2001
- 2001-02-26 ZA ZA200101566A patent/ZA200101566B/en unknown
- 2001-02-26 ZA ZA200101567A patent/ZA200101567B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200101567B (en) | 2003-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1009753B1 (en) | Hypoxia-regulated genes | |
US5861485A (en) | Polypeptides involved in body weight disorders, including obesity | |
US7524935B2 (en) | Sequences characteristic of hypoxia-regulated gene transcription | |
AU5810999A (en) | Sequences characteristic of hypoxia-regulated gene transcription | |
US6545139B1 (en) | DNA sequence encoding the p99 gene and kits for the detection of neoplasia | |
NZ543295A (en) | DNA sequences for human angiogenesis genes | |
US6323329B1 (en) | Nucleic acid sequences of genes encoding high mobility group proteins | |
US5741666A (en) | Compositions and methods, for the treatment of body weight disorders, including obesity | |
JP2003510349A (en) | Genes required for striatal function, their use, and compounds for regulating them | |
US20030104973A1 (en) | Hypoxia-regulated genes | |
US7973156B2 (en) | Hypoxia-regulated genes | |
US5952223A (en) | Compositions for the diagnosis and treatment of Chediak-Higashi syndrome | |
WO1997034914A9 (en) | Compositions for the diagnosis and treatment of chediak-higashi syndrome | |
ZA200101566B (en) | Sequences characteristic of hypoxia-regulated gene transcription. | |
US6514935B1 (en) | Methods of treating hypertension | |
US20050004065A1 (en) | Hypoxia regulated genes | |
US6258557B1 (en) | Smooth muscle cell LIM promoter | |
AU2002328200B2 (en) | DNA sequences for human angiogenesis genes | |
JP2001025389A (en) | Tsa7005 gene |